Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline

Executive Summary

With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.

Advertisement

Related Content

PTI’s Remoxy: Negative FDA Panel Review May Be The End Of Abuse-Deterrent Opioid's Road
Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request
Endo Continues To Expand Generics Business With Par Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel